Centessa Pharmaceuticals announced that it has received clearance of its Investigational New Drug, IND, application from the U.S. Food and Drug Administration, FDA, to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors. LB101 is the first product candidate developed using the Company’s proprietary LockBody technology. "We are very excited to be bringing our first LockBody candidate to the clinic and to be advancing a potentially transformative technology for patients with solid tumors," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "The clearance of our IND for LB101 is an important milestone for our company as we have an ambitious strategy to advance multiple potential LockBody candidates in areas where there is a significant need for new cancer treatment options. We look forward to initiating the Phase 1/2a trial of LB101 as soon as possible."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNTA:
- Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
- Centessa announces additional data OLE of Phase 2a SerpinPC study
- Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
- Centessa appoints Karen Anderson as new Chief People Officer